GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (STU:I9DN) » Definitions » Cyclically Adjusted PB Ratio

Arbutus Biopharma (STU:I9DN) Cyclically Adjusted PB Ratio : 0.95 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Arbutus Biopharma's current share price is €2.994. Arbutus Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €3.15. Arbutus Biopharma's Cyclically Adjusted PB Ratio for today is 0.95.

The historical rank and industry rank for Arbutus Biopharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:I9DN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.24   Med: 0.9   Max: 8.34
Current: 0.95

During the past years, Arbutus Biopharma's highest Cyclically Adjusted PB Ratio was 8.34. The lowest was 0.24. And the median was 0.90.

STU:I9DN's Cyclically Adjusted PB Ratio is ranked better than
64.01% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs STU:I9DN: 0.95

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Arbutus Biopharma's adjusted book value per share data for the three months ended in Mar. 2024 was €0.585. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.15 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted PB Ratio Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 1.08 1.13 0.64 0.71

Arbutus Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.63 0.56 0.71 0.75

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted PB Ratio falls into.



Arbutus Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arbutus Biopharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.994/3.15
=0.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Arbutus Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.585/131.7762*131.7762
=0.585

Current CPI (Mar. 2024) = 131.7762.

Arbutus Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 3.505 100.560 4.593
201409 3.326 100.428 4.364
201412 3.182 99.070 4.232
201503 10.141 99.621 13.414
201506 9.656 100.684 12.638
201509 9.042 100.392 11.869
201512 9.213 99.792 12.166
201603 8.846 100.470 11.602
201606 7.005 101.688 9.078
201609 6.769 101.861 8.757
201612 3.509 101.863 4.539
201703 3.213 102.862 4.116
201706 2.843 103.349 3.625
201709 2.551 104.136 3.228
201712 2.036 104.011 2.579
201803 1.679 105.290 2.101
201806 1.760 106.317 2.181
201809 1.418 106.507 1.754
201812 1.149 105.998 1.428
201903 0.807 107.251 0.992
201906 0.501 108.070 0.611
201909 -0.811 108.329 -0.987
201912 -0.897 108.420 -1.090
202003 -0.865 108.902 -1.047
202006 -0.953 108.767 -1.155
202009 -0.484 109.815 -0.581
202012 -0.429 109.897 -0.514
202103 -0.332 111.754 -0.391
202106 -0.462 114.631 -0.531
202109 -0.235 115.734 -0.268
202112 1.034 117.630 1.158
202203 1.012 121.301 1.099
202206 0.974 125.017 1.027
202209 0.962 125.227 1.012
202212 0.820 125.222 0.863
202303 0.814 127.348 0.842
202306 0.745 128.729 0.763
202309 0.667 129.860 0.677
202312 0.572 129.419 0.582
202403 0.585 131.776 0.585

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arbutus Biopharma  (STU:I9DN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arbutus Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (STU:I9DN) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma (STU:I9DN) Headlines

No Headlines